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Rabbit immune sera and mouse monoclonal ntibodies were raised against the synthetic peptlde Tyr-Cys- 
Glu-Ile-Ile-Val matching in sequence residues 1:!7-132 of the cc-subunit of all nicotinic acetylcholine recep- 
tors sequenced so far. Representative cholinergic ligands did not interfere with the binding of these antibod- 
ies to the receptor from Torpedo marmorata, indicating that this sequence is not part of the binding sites 
for cholinergic hgands. The applicability of antigenic sites analysis to the mapping of functional sites on 
receptor proteins is discussed. 
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1. INTRODUCTION 
Although the nicotinic acetylcholine receptor 
from electric tissue has been studied in more detail 
than any other neurotransmitter receptor [l], a full 
understanding of its structure-function relation- 
ship has not yet been achieved. With its genes 
cloned and its primary structure elucidated [2-81, 
however, the receptor is now accessible to new ap- 
proaches in this direction. These include chemical 
modification of defined sequence positions, site- 
directed mutagenesis and, as we propose here, the 
application of antibodies prepared against short 
synthetic peptides matching in sequence predeter- 
mined sites on the receptor surface. Employing 
such antibodies, the sequence positions of their an- 
tigenic sites can be tested as to whether they 
overlap with functional sites of the receptor. 
To obtain antibodies of the required specificity, 
the following conditions must be met: (i) The syn- 
thetic peptides must be sufficiently long to provide 
antigenic properties (4-6 amino acids) [9]. 
However, to avoid any ambiguity in antigenic site 
Abbreviations: AChR, nicotinic acetylcholine r ceptor; 
BSA, bovine serum albumin; mAb, monoclonal 
antibody 
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definition, this limiting size should not be exceed- 
ed. (ii) The obtained antibodies must specifically 
recognize the peptide region of the peptide-carrier 
conjugate employed in the immunisation pro- 
cedure. (iii) The antibodies must recognize the 
receptor both in its natural conformation and 
when denatured. As outlined in this report for one 
such pre-determined site at the receptor, these con- 
ditions were met as follows: The synthetic peptide 
Tyr-Cys-Glu-Ile-Ile-Val matching in sequence 
residues 127-132 of the a-subunit of all nicotinic 
receptors sequenced so far [7] was conjugated to 
BSA. Mouse monoclonal antibodies and antisera 
in rabbits were raised against this conjugate. The 
monoclonal antibodies selected for further studies 
specifically recognized the peptide portion of the 
conjugate and the membrane-bound and purified 
recptor from Torpedo marmorara under natural 
conditions and after denaturation. The obtained 
rabbit immune sera contained antibodies directed 
against BSA, the specific peptide-BSA conjugate 
and the receptor. Response to the latter two an- 
tigens remained strong even in the presence of ex- 
cessive amounts of BSA, indicating that some of 
the antibodies in the serum recognized antigenic 
elements that are identical in both the synthetic 
peptide and the acetylcholine receptor. 
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The related segments of the P,y and S-subunits 
of the receptor from T. californica (and by in- 
ference of the T. marmorata receptor) show partial 
homology with the hexapeptide of the a-subunit 
but do not contain a negatively charged residue. 
Since a carboxylate group is generally assumed to 
be required as an attachment point for the 
trimethylammonium moiety of acetylcholine 
[l,lO], the a-peptide therefore contains a central 
element of distinction from the homologous se- 
quence portions of the other subunits. To test 
whether the particular peptide region of the u- 
subunit is part of an acetylcholine binding site, 
anti-peptide antibody binding to the native recep- 
tor was studied in the presence and absence of 
representative cholinergic ligands. The ligands 
tested did not interfere with antibody binding. The 
antibodies directed against the synthetic peptide 
were also tested as to whether they competed with 
the binding to the receptor of monoclonal an- 
tibodies raised against the whole receptor protein 
and shown to competitively affect ligand binding 
[ll]. Again, no interference was observed sug- 
gesting that residues 127-132 of the a-subunit are 
not part of the binding sites for cholinergic ligands 
at the receptor. 
2. MATERIALS AND METHODS 
Membrane fragments and purified acetylcholine 
receptor from T. marmorata, purification and 
radioactive labeling of cu-cobratoxin and the 
monoclonal antibodies were performed according 
to [ll-151. 
Preparation of peptide-carrier conjugate: The 
hexapeptide Tyr-Cys-Glu-Ile-Ile-Val was syn- 
thesized by a solid phase method [16] and purified 
by high-performance liquid chromatography. Its 
purity was further established by amino acid 
analysis and sequence determination. We thank Dr 
M. Engelhard and B. Pevec from our institute for 
the synthesis and characterization of the peptide. 
The peptide was selectively coupled at its N- 
terminal to BSA by reaction with glutaraldehyde 
]171. 
Preparation of antisera and monoclonal an- 
tibodies: Female New Zealand White rabbits were 
immunized intradermally with 3 mg peptide-BSA 
conjugate in Freund’s complete adjuvant followed 
by booster injections (every 3 weeks) of the same 
amount of antigen in incomplete adjuvant. 
To obtain monoclonal antibodies to the syn- 
thetic peptide, young female Balb/c mice were in- 
jected intravenously with 3 mg peptide-BSA con- 
jugate. Three days after a booster injection, the 
spleens of the immunized mice were removed and 
cell hybridization, cell cloning and clone selection 
were performed as in [11,15]. 
Antibody binding assays: Enzyme-linked im- 
munosorbent assays (ELISA) of monoclonal an- 
tibodies were performed according to [ll] except 
that the commercially available screening kit NEN- 
NE1 602 (NEN) employing o-phenylendiamine as 
substrate was used. Purified a- and J-subunits 
were kindly provided by Dr H.-W. Meyers from 
our laboratory, ELISAs of rabbit immune sera 
were performed by the same procedure except that 
anti-rabbit IgG antibodies (NEN, Dakopatts) were 
employed. 
3. RESULTS AND DISCUSSION 
The hexapeptide Tyr-Cys-Glu-Ile-Ile-Val was 
synthesized and coupled to BSA using 
glutaraldehyde as cross-linking agent [ 171. An- 
tibodies against the conjugate were raised by con- 
ventional immunisation of rabbits and by the 
murine hybridoma technique [ 181. Hybridoma 
clones selected for further studies showed high 
readings in ELISAs with the peptide-BSA con- 
jugate and the acetylcholine receptor as antigen 
both before and after heat denaturation, but only 
background readings with BSA as antigen (table 
1). Thus, the selected cell-lines Pl-P3 produced 
antibodies specific for the peptide region of the 
conjugate, and these antibodies cross-reacted with 
the native and denatured receptor. The antibodies 
appeared to exclusively react with the a-subunit of 
the receptor (fig.1). Since other regions of this 
subunit have at most two positions in common 
with the selected hexapeptide, specific recognition 
by the anti-peptide antibody of the sequence seg- 
ment homologous with the synthetic peptide is very 
likely. 
The obtained mouse monoclonal antibodies to 
the hexapeptide were tested as to whether their bin- 
ding to the receptor can be blocked by rabbit im- 
mune sera raised against he same synthetic peptide 
or against he whole receptor protein. As shown in 
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Table 1 
Binding of monoclonal antibodies to selected antigens’ 
Hybridoma clone Antigen 
mAb Internal code Peptide BSA Acetylcholine receptor 
conjugate 
Purified Membranes Denatured 
Pl Cl-NII-Al 2.0 0.2 2.6 2.5 2.6 
P2 Cl-NIII-Al 2.6 0.4 2.6 2.6 2.3 
P3 C2-NI-C2 2.6 0.5 2.6 2.6 2.3 
P5 Cl-NH-B3 2.0 0.2 0.7 1.2 0.9 
P6 Cl-NI-Al 2.6 2.6 2.6 2.6 2.6 
P7 Cl-XI-Al 0.4 2.6 0.2 0.7 0.4 
’ Absorbance readings at 490 nm employing the ELISA described in section 2. Readings of 0.1-0.5 Ajvo units were 
considered background 
fig.2, the serum from rabbits immunized with the 
specific hexapeptide interfered the strongest while 
only weak interference was observed with an anti- 
receptor immune serum. Thus, the preselected se- 
quence segment recognized by the anti-peptide an- 
tibodies appears to be located at the receptor 
surface. 
To test whether the preselected sequence seg- 
ment is related to a binding site for cholinergic 
ligands, binding of monoclonal anti-peptide an- 
Fig. 1. Enzyme-linked immunosorbent assay of anti- 
peptide antibodies with purified a-subunits (x) and 6- 
subunits (0) of the AChR from T. marmorata. Serial 
dilution curves of (left) anti-receptor antiserum and 
(right) anti-hexapeptide antiserum. Specificity for the LY- 
subunit is observed only with the anti-peptide antibodies 
(right) but not with the anti-receptor serum (left). 
tibodies to the receptor was studied in the presence 
and absence of representative cholinergic ligands 
(cu-cobratoxin, carbamoylcholine, decametho- 
nium, tubocurarine). As shown in fig.3, these 
ligands even at very high concentrations did not 
compete with binding of the anti-peptide anti- 
bodies to the receptor. Thus, the sequence segment 
homologous with the synthetic peptide apparently 
;2 
dllutfon of ont~serum 
Fig.2. Competition binding to membrane fragments 
from T. marmorata of mAb P3 and rabbit immune sera. 
Serial dilution curves of mouse hybridoma culture 
supernatant mAb P3 in the presence of rabbit (0) anti- 
hexapeptide antiserum (1: 20 in PBS), (0) anti-receptor 
antiserum (1: 100 in PBS), and (x) preimmune serum. 
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Fig.3. Binding of mAb P3 to AChR-rich membrane 
fragments in the presence and absence of representative 
cholinergic ligands. The serial dilutions were obtained by 
first adding 200~1 of the respective ligand solution to 
each cuvette of a strip of 10. After preincubation for 
15 min (toxin 2 h), 200~1 of culture medium was added 
to cuvette 1 and mixed; 200 pl of the contents was then 
transferred to cuvette 2, and so on. (x) Serial dilution in 
the absence of ligand; (0) a-cobratoxin at initially 
1 PM; (A) carbamoylcholine at initially 1 mM; (0) 
tubocurarine at initially 1 mM; and (0) decamethonium 
at initially 1 mM. 
does not contain structural elements of a binding 
site for cholinergic ligands. 
This conclusion is supported by competition 
binding studies of a rabbit anti-peptide serum and 
the same representative ligands to the receptor (not 
shown). In addition, application of the rabbit 
serum permits testing whether the sequence seg- 
ment defined by the synthetic peptide overlaps 
with any of the known antigenic sites at the recep- 
tor [ 11,191. Since we did not observe any competi- 
tion in binding between the rabbit serum and an- 
tibodies from our library of monoclonals [l 11, 
such overlap apparently does not occur. 
4. CONCLUSIONS 
We describe here an immunogenic approach to 
the mapping of functional sites at the surface of 
the receptor. Since antigenic sites are defined by 
only a few amino acids [9,22], the employed 
method of site localization is the more reliable the 
shorter the synthetic peptides used (with the limita- 
tion of a minimal number of 4-6 amino acids). 
Long peptides, in contrast, may provide several or 
many antigenic determinants with homologies to 
other sequence regions of the receptor. This dif- 
ference in approach to previous studies of similar 
aim [23] should be emphasised. 
Antigenic site analysis in the way described here 
is limited in local resolution to the minimal size of 
the peptide required to evoke an immune response. 
In addition, only surface regions of a protein can 
be probed in this way. In these respects the method 
is inferior to site-specific chemical modification 
and to site-directed mutagenesis. However, the ad- 
vantage of the immunogenic approach lies in its 
simplicity and in the additional value specific sur- 
face markers to a functional site may have in the 
quantitative analysis of this function. 
Several models of the 3-dimensional structure of 
the acetylcholine receptor have been proposed 
[7,24-271. These are rather specific with respect o 
the transmembrane regions of the receptor but 
vague with respect to the structure of the ex- 
tramembranous regions. Several alternative se- 
quence regions can therefore be envisioned as the 
positions of the ligand binding sites [10,26,27]. 
The immunogenic approach described here pro- 
vides a rapid means to test such preconceived ideas 
on the structure-function relationship of receptor 
proteins with known primary structure. 
In the specific case of the preselected sequence 
segment of the acetylcholine receptor (residues 
127- 132) we conclude from our studies that it does 
not contain structural elements involved in ligand 
binding. 
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